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BACKGROUND: Vitamin D is vital for calcium homeostasis and skeletal health, has 
immunomodulatory effects and is involved in the regulation of differentiation and proliferation 
of many different cell types. Adipose tissue is an important metabolic organ and a major organ 
for vitamin D storage. Although adipose tissue expresses enzymes for vitamin D metabolism 
and the nuclear vitamin D receptor, the role of vitamin D and its function in adipose tissue is 
not fully explored.  
METHOD: This thesis applies an ether solvent extraction method based on the SIMPLEX 
method to simultaneously extract lipids and metabolites from 102 adipose tissue samples from 
a RCT consisting of 51 participants divided to vitamin D (25 participants) or placebo (26 
participants) intervention. Extracted lipid samples were analyzed with UHPLC-MS using an 
AcquireX data acquisition workflow. The lipids were then identified and quantified with 
LipidSearch. Multivariate data analysis was performed to study the differences between the 
vitamin D and placebo group. Other analyses, such as pathway analysis, was also performed.  
RESULTS: A total of 633 lipid were identified and quantified. No separation was seen in the 
unsupervised PCA, though applying supervised OPLS demonstrated a separation between 
supplementation of vitamin D and placebo when using group affiliation as discrimination 
criterion. Using serum 25(OH)D levels as discrimination criterion showed better separation 
than when subcutaneous adipose tissue vitamin D levels was used, indicating that lipids in 
adipose tissue may be affected by vitamin D in other parts of the body than in adipose tissue, 
e.g. the liver. Out of the 20 most important lipids causing the separation, only 2 were significant 
(p≤0.05). 6 out of the 20 contained the fatty acid 4:0 and 4 out of 20 contained either 20:4 or 
20:5, possibly indicating vitamin D’s activity in production of butyrate and eicosanoid 
metabolism. Pathway analysis only identified the glycerophospholipid metabolism pathway, 
though not statistically significant.  
CONCLUSION: The results showed a difference in the lipidome between vitamin D and 
placebo intervention. Though through further examination of the cause of separation, the 
findings in this thesis were not of statistical significance. Nevertheless, there is much left 
unexplored and worth further investigation. The metabolite fractions are stored at -80ºC 
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1.1 Background  
Vitamin D is not only a vital for calcium homeostasis and skeletal health, but also has 
immunomodulatory effects in addition to being involved in the regulation of differentiation and 
proliferation of many different cell types. Adipose tissue is an important metabolic organ with 
an essential role in energy homeostasis along with being a major organ for vitamin D storage. 
Although adipose tissue expresses enzymes for vitamin D metabolism and the nuclear vitamin 
D receptor, the role of vitamin D and its function in adipose tissue is not fully explored. This 
thesis aims to detect changes in the lipidome in humans occurring upon vitamin D 
supplementation compared to placebo with the help of lipidomics technologies.  
1.2 Vitamin D 
Vitamin D is known as the sunshine vitamin. It was first in the industrial revolution in northern 
Europe that the importance of sunlight for human health was shown. People began gathering in 
the cities and living in dwelling in close proximity to each other. The atmosphere became 
polluted as a result of burning of wood and coal. Because of this industrialization children had 
little direct exposure to sunlight, and as a result developed rickets. Rickets is the failure of 
mineralization of growing bone and cartilage and was first reported in the 17th century by Daniel 
Whistler and Francis Glisson in England. In 1822, Sniadecki (1) observed that children in the 
rural areas outside of Warsaw did not develop the disease. Thus, he hypothesized that rickets 
was caused by the lack of exposure to direct sunlight in the children residing in the cities, 
compared to children residing on the farms. In 1890, Palm (2) supported this hypothesis as he 
observed that children from areas close to the equator were free of this disease despite having 
poor nutrition. Regardless of Sniadecki’s and Palm’s observations, by 1900 the disease rickets 
was so common, the disease became an endemic (3). Eventually, it was discovered that 
exposure to sunlight and cod liver oil could both prevent and treat rickets. Once vitamin D was 




1.2.1 Metabolism and Biological Functions 
 
Figure 1-1Structure of vitamin D3 and its metabolites. Created with ChemDoodle. 
Vitamin D is a fat-soluble prohormone normally produced in the skin through ultraviolet 
irradiation of a derivative of cholesterol, 7-dehydrocholesterol, to produce previtamin D, which 
then isomerize to vitamin D3. Vitamin D3 is a prohormone and the natural form of vitamin D 
produced in skin, while vitamin D2 is produced from irradiation of ergosterol (6). The cutaneous 
production of vitamin D3 is regulated. At times of prolonged exposure to solar UVB radiation, 
solar photoproducts inactive on calcium metabolism, such as tachysterol and lumisterol, is 
produced. This prevents sun induced vitamin D intoxication (7). The production of vitamin D3 
in the skin is influenced by skin pigmentation, use of sunscreen, air pollution, time of the day, 
altitude, latitude, and season. Because of the increase in the solar zenith angle during winter, 
early mornings, and late afternoons, the solar UVB photons have a longer travel path through 
the ozone layer, which absorbs the UVB photons. For this reason, little to no vitamin D is made 
in skin in winter at above and below approximately 33º latitude. Correspondingly, vitamin D is 
only synthetized between 10 am and 3 pm at the equator and far southern and northern regions 
of the world where the sun shines almost 24 hours a day (7). For this reason, the RCT in this 
thesis is conducted in the winter of Tromsø, where little to no vitamin D is produced in the skin. 
The enzyme vitamin D 25-hydroxylase (CYP2R1) converts vitamin D into 25-hydroxyvitamin 
D (25(OH)D), also known as calcidiol, in the liver. The active form of vitamin D, 1,25-
dihydroxyvitamin D (1,25(OH)2D) also known as calcitriol, is then generated from 25(OH)D 
by the enzyme 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1). In the kidneys this activity 
generates endocrine supply of 1,25(OH)2D, while in some extrarenal tissues with CYP27B1 





In the circulation, the majority of vitamin D is bound to vitamin D binding protein (DBP) with 
high affinity. Vitamin D bound to DBP is transported within the organism, facilitating vitamin 
D access to various cell types and tissues along with regulating the total amount of vitamin D 
available for the organism (8). Vitamin D exerts most, if not all, of its physiological effects 
through its metabolite 1,25(OH)2D. 1,25(OH)2D acts as a nuclear hormone, as it is the only 
high affinity ligand for the transcription factor vitamin D receptor (VDR) (9). 1,25(OH)2D binds 
to nuclear VDR, which then binds to retinoic acid X receptor (RXR) to form a heterodimer. 
The VDR-RXR complex binds to specific nucleotide sequences in the DNA known as vitamin 
D response elements (VDRE). As a result, the gene’s activity can be either up- or down-
regulated (7). VDR is expressed in the majority of human tissues and cell types (9).  
Vitamin D, in its active form, is essential for intestinal calcium absorption and plays a central 
role in maintaining calcium homeostasis, phosphorus homeostasis and skeletal integrity. In 
addition to this 1,25(OH)2D also regulates cell proliferation and differentiation, cellular growth 
and hormone secretion (10, 11).  
Once 1,25(OH)2D is formed it enters the circulation and travels to the small intestine and bone, 
the principal calcium-regulating target tissues. 1,25(OH)2D binds VDR in the small intestine 
and activate vitamin D responsive genes to enhance intestinal calcium and phosphorous 
absorption. However, when dietary calcium is insufficient 1,25(OH)2D travels to the bone and 
interact with osteoblast, which stimulate the formation of osteoclasts. This results in increased 
osteoclastic activity, which removes the calcium stores from the bone and deposits it into the 
blood to maintain calcium homeostasis (7, 12). In a vitamin D deficient state there is a decrease 
of the intestinal calcium absorption and the total maximal reabsorption of phosphate. Low 
ionized calcium levels stimulate the secretion of parathyroid hormone (PTH), which increases 
the tubular reabsorption of calcium in the kidneys and increases CYP27B1 activity and causes 
increased 1,25(OH)2D synthesis (11). Secondary hyperparathyroidism also results in PTH-
induced loss of phosphorous into the urine and decreased phosphorus absorption in the 
intestines. This leads to low fasting serum phosphorous concentrations. Together with low 
serum calcium concentration it often results in an insufficient calcium-phosphate product. 
Calcium-phosphate product is important for the mineralization process. In insufficient 
conditions, it causes mineralization defects which results in rickets in children and osteomalacia 




As VDR is expressed in majority of human tissues and cell types, including heart, stomach, 
pancreas, brain, skin, gonad, prostate, breast and activated T- and B-lymphocytes, vitamin D 
also has a multitude of noncalcemic functions (11, 13). Thus, vitamin  D has been associated 
with reducing the risk of many types of cancer, diabetes mellitus, cardiovascular disorders and 
other illnesses (7).  
 
Figure 1-2 Metabolism and biological functions of vitamin D. Created with BioRender.com 
1.2.2 Vitamin D Status, Sources and Supplementation Recommendation 
Vitamin D is a micronutrient which is needed for optimal health throughout the whole life (14). 
If vitamin D synthetized in the human skin upon exposure to UV light is insufficient, intake of 
adequate vitamin D from diet or dietary supplements is essential (14). Vitamin D is found 
naturally only in very few foods. Fatty fish, such as salmon, mackerel and sardines, and fish 
liver oils, such as cod liver oil, are good sources of vitamin D, as well as wild mushrooms or 




cholesterol content eggs are a poor source for vitamin D. Unless fortified, milk contains very 
little to no vitamin D content, while dairy products, like butter and cheese, shows higher vitamin 
D content though the amount is still low in a serving size (3, 14).  
There is a consensus that 25(OH)D is to be used as an assessment of vitamin D status as 
25(OH)D reflects dietary supply and the dermal production, though other novel markers has 
been investigated and shown to be worthy of further investigation (10). Optimal serum 
concentrations of 25(OH)D is most commonly defined as the concentration that maximally 
suppresses serum PTH. Estimates of optimal 25(OH)D concentrations reached with this 
criterion vary widely from 20 to 110 nmol/L, and no consensus has been reached. In a review, 
optimal 25(OH)D concentrations were estimated for multiple health outcomes, including bone 
mineral density and fracture risk reduction, dental health, lower-extremity function, and 
colorectal cancer prevention. Data in this review suggested that the most advantageous target 
concentration is 75 nmol/L and optimal concentration is between 90 and 100 nmol/L (15). 
Institute of Medicine states that serum concentrations below 30 nmol/L is associated with the 
risk of negative effects on bone health while serum concentrations above 50 nmol/L is sufficient 
for 97.5% of the population (16). According to the Norwegian guidelines, serum 25(OH)D 
concentrations between 25-50 nmol/L is considered suboptimal, while 12.5-25 nmol/L is 
considered deficiency. Similarly, vitamin D levels below 12.5 nmol/L is considered as a severe 
deficiency. Thus, the general aim is to achieve 25(OH)D concentrations above 50 nmol/L which 
is considered sufficient (17). The RCT in this thesis includes participants with 25(OH)D 
concentration in the rang 25-45 nmol/L, which is in the range considered suboptimal.  
Table 1-1 Reference values for vitamin D status 





25-50 nmol/L Suboptimal 
12.5-25 nmol/L Deficiency 
<12.5 nmol/L Severe deficiency 
 
To reach the level of vitamin D sufficiency, Institute of Medicine recommend a dietary vitamin 
D intake of 600 IU/day (15 µg/day) from 1-70 years of age, including pregnant and lactating 




recommends a dietary intake of 400 IU/day (10 µg/day) between the age of 1-74 years, and 800 
IU/day (20 µg/day) for those who has passed the age of 74 years (18).  
 
1.3 Adipose Tissue 
The adipose tissue (AT) was previously considered as a simple storage site, but it is now 
recognized as an important metabolic organ and has an essential role in energy homeostasis 
(19). AT in humans consist of two major types, white adipose tissue (WAT) and brown adipose 
tissue (BAT). WAT is made up of subcutaneous WAT (SAT) and visceral WAT (VAT) around 
internal organs. BAT participates in non-shivering thermogenesis through lipid oxidation, while 
WAT functions primarily as insulation and energy storage (20). WAT has a limitless capacity 
for triglyceride storage vital for survival. During a meal, the rise in insulin, glucose and lipids 
stimulates triglyceride formation and storage in WAT and liver. Opposite, when there is a fall 
of insulin during fasting glycogen breakdown and lipolysis is triggered through activation of 
the nervous system and elevation of glucagon, glucocorticoids and epinephrine (19).  
Adipocytes has shown to secrete cytokines, hormones, and peptides, collectively termed 
adipokines. One of the most well studied adipokines is leptin. Leptin inhibits appetite and 
stimulate satiety by regulating neural circuits in the brain and is secreted in response to food 
intake. Circulating leptin is elevated in obesity, but because of hypothalamic leptin resistance 
obesity is aggravated, by inhibiting appetite control and lipid oxidation. Another adipokine is 
adiponectin. Adiponectin stimulates lipid oxidation and anti-inflammatory responses and 
through this exerts antidiabetic effects, anti-obesity and alleviates insulin resistance (20). 
1.3.1 Vitamin D in Adipose Tissue 
AT is the main storage site of vitamin D and expresses VDR and enzymes involved in vitamin 
D metabolism. In addition, it has been shown that vitamin D regulates adipogenesis as well as 
adipocyte apoptosis (21).  
AT was discovered to be a principle storage site using radiolabeled vitamin D given to vitamin 
D-deficient weanling rats orally. It was shown that within 24 hours of administration, a 
significant amount of radioactivity was present in the AT. The release of vitamin D from the 
AT of the rats was very slow after the vitamin D treatment ceased. After 6 weeks of the vitamin 




D released was proportional to the concentration of vitamin D present in AT, AT shows 
indications that it has the characteristics of a depot for the storage of vitamin D as well as the 
release (22). In a more recent human study, it has been demonstrated that a considerable amount 
of vitamin D is stored in SAT. After 3-5 years of supplementation of 20 000 IU vitamin D per 
week, vitamin D content in SAT increased by approximately 6-fold compared to placebo (23).  
Adiposity is a serious public health problem associated with vitamin D insufficiency due to the 
decreased bioavailability of vitamin D because of its deposition in body fat compartments. BMI 
is inversely related to serum 25(OH)D, but there is no evidence for a BMI lowering effect by a 
higher 25(OH)D (24). Present data suggests that, in obese subjects, the vitamin D system is 
altered. This may have consequences for the development of obesity and its co-morbidities. 
The expansion of adipose tissue in obesity is associated with an increase in the accumulation 
of macrophages in the tissue. Since macrophages are known to hydroxylate 25(OH)D to 
1,25(OH)2D, this may facilitate the local conversion of 25(OH)D (25).  
It has been reported that CYP27B1 is expressed in mouse 3T3-L1 preadipocytes and in adipose 
tissue of Wistar rats. It is also shown to be expressed by Simpson-Golabii-Beymel syndrome 
human adipocytes and preadipocytes as well as human mammary adipocytes. Therefore, 
adipocytes could be involved in local synthesis and degradation of vitamin D. Human 
mammary adipocytes demonstrated bioactivation of 25(OH)D to 1,25(OH)2D, together with 
the release of 1,25(OH)2D (25). 
 
1.4 Omics  
The addition of the suffix “omics” to a molecular term implies a comprehensive, or global, 
assessment of a set of molecules (26). Omics technology includes genomics, transcriptomics, 
proteomics, and metabolomics, and are high-throughput technologies that substantially increase 
the number of genes/proteins/metabolites that can be detected simultaneously. With the use of 
omics technologies there is a potential to relate complex mixtures to complex effects through 
gene/protein/metabolites quantification profiles. The primary aim of omics is the nontargeted 
quantification of all gene products in a biological sample, namely transcripts, proteins and 






Metabolomics is the study of the metabolome, commonly defined as the complete collection of 
metabolites, small molecules (<1 500 Da), found in an organism, biofluid, organ, cell, or 
organelle. In other words, metabolites can consist of many endogenous compounds such as 
lipids, carbohydrates, short peptides, amino acids, nucleic acids and others, that are produced 
endogenously during catabolism and anabolism, as well as exogenous compounds (28, 29).  
Metabolomics has, historically, been primarily used to diagnose diseases or detect pathological 
conditions, most likely since metabolomics has been considered as an extension of clinical 
chemistry. Though, while clinical chemistry typically focuses on one or two compounds at a 
time, metabolomics looks at hundreds at a time. Because of the metabolomics ability to measure 
large numbers of varying metabolites, it has become particularly attractive to studying and 
diagnosing metabolic diseases (28).  
1.4.2 Lipidomics  
Lipidomics is the science of the large-scale determination of individual lipid species (30), and 
belong to the last step of the “omic” cascade, the metabolomics. The metabolome represents 
the qualitative and quantitative information on all metabolites occurring in a biological system, 
reporting the actual state of the organism. Therefore, it is most convenient for biomarker 
discoveries of pathological states of an organism (31). Different techniques can be used for 
metabolomics/lipidomics, such as nuclear magnetic resonance spectroscopy (NMR) or UV, but 
UPLC-MS provides more identifications and better quantitation with the exception of target 
analysis (30).  
Lipids are a heterogeneous pool of compounds that contain either fatty alkyl, fatty acyl, 
sphingosine, or isoprene moieties as their hydrophobic building blocks. The lipids are generally 
classified into eight categories: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, 
sterols, prenol lipids, saccharolipids and polyketides. Each of these categories consists of 
further lipid classes and subclasses (30). This leads to a total of 45 144 lipids in the LIPID 
MAPS Structure Database (LMSD). Among these 23 191 of the compounds are curated and 
the remaining 21 953 are computationally generated lipids (November 2020) (32). Thus, 
lipidomics is challenging as the lipidome comprises thousands of different molecular species 
highly diverse in chemical structure and composition as well the occurrence of molecular 




1.5 Sample Preparation  
Appropriate sample preparation is an essential aspect of quantitative bioanalysis. In the sample 
preparation interfering matrix compounds should be removed to avoid clogging and soiling the 
instrument, in addition to improving the sensitivity, selectivity and reliability of analyses. 
Factors such as the analytes characteristics, their expected concentration, sample size and 
matrix, as well as the availability of analytical techniques are important when selecting an 
appropriate sample preparation method. Commonly applied sample preparation techniques 
include protein precipitation, solid-phase extraction, and liquid-liquid extraction (34). 
Liquid-liquid extraction is a separation process consisting of the transfer of the solute from one 
solvent to the another. The two solvents used are immiscible or partially miscible with each 
other, with one of the solvents usually being water or an aqueous mixture and the other a non-
polar organic liquid. Liquid-liquid extraction, like all extraction processes, consists of two 
steps, mixing followed by phase separation. Both steps are important to consider when selecting 
solvents and modes of operation (35). Liquid-liquid extraction is in general simpler and less 
time consuming compared to the other extraction methods and may be applicable to almost all 
laboratories using large variety of available solvents. It is also less expensive as well as more 
flexible as several samples may be prepared in parallels. But large volumes of flammable and/or 
toxic solvents, mutual solubility of analytes in both phases, as well as emulsion formation 
should be taken into consideration (34). 
 
1.6  High-Performance Liquid Chromatography and Ultra-High-
Performance Liquid Chromatography  
Chromatography is a term for several similar techniques that separates different molecular 
species in a mixture, based on differences in rates of migration when the sample components 
are transported through a stationary phase by a mobile phase. In high-performance liquid 
chromatography (HPLC) the sample is introduced to a flowing liquid mobile phase that passes 
a stationary phase, which is typically in the form of a column packed with very small porous 
particles. The mobile phase is moved through the stationary phase by a pump (36, 37).  
A sample is made up of analytes, the molecules of interest, and matrix, the rest of the 
components. The sample is injected into the mobile phase as a small volume just before the 




the mobile phase, but not stronger eluting. Difference in migration of the components in the 
sample depends on the equilibrium distribution of each component between the stationary phase 
and the mobile phase. The more time a component spends in the stationary phase, the longer 
the retention and opposite. Therefore, the migration is determined by the composition of the 
mobile phase, the composition of the stationary phase and the temperature. Detectors provide 
an electronic response to the analytes when they elute, which is then processed by a computer 
system that prints the results as chromatograms (36, 37).  
Ultra-high-performance liquid chromatography (UPLC) is similar to HPLC, the difference is 
in the size and shape of the silica particles. In HPLC the size of the particles in the column is 
usually 3-10 µm, while in UPLC the diameter can be below 2.5 µm. The columns in UPLC is 
also often shorter in length due to the higher separation performance of the smaller particles. 
The very small particles also require a significantly higher operation pressure for the mobile 
phase. UPLC methods are used increasingly due to better and faster separation, major savings 
in the consumption of mobile phase and lower detection limits (36, 37).  
Reversed phase HPLC is the most common HPLC technique. In reversed phase 
chromatography the stationary phase is hydrophobic, and the mobile phase is a polar aqueous 
solution. The stationary phases for reversed phase are typically made of silica derivatized with 
reagents to form a hydrophobic surface, typically by binding hydrophobic groups to the silanol 
groups, for example long hydrocarbon chains such as C18. The main separation mechanism in 
reversed phase chromatography is hydrophobic interaction. Therefore, the nonpolar analytes 
are retained strongly, while polar analytes elute earlier. The main forces of interaction are van 
der Waal’s forces. Van der Waal’s forces are relative weak forces, but they are present in a 
large number per molecule. Thus, the interaction increases with the molecular size. The mobile 
phases consist of mixtures of water and one or more organic solvents which must be miscible 
with water. The organic solvents modify the strength of the mobile phase. The strength of the 
mobile phase increases with the increase of the organic solvents, and the retention of the 
analytes decrease. Small amounts of buffers can also be added to control the pH and counter 





1.7 Mass Spectrometry  
Mass spectrometry (MS) is performed by using an instrument called mass spectrometer and 
measures mass over charge (m/z) of atoms, molecules, or fragments of molecules. A mass 
spectrometer is built from three components, an ion source, a mass analyzer, and a detector. In 
the ion source, the analyte molecules are ionized to molecular ions or pseudo molecular ions. 
The mass analyzer then separates the ions according to their m/z.  Finally, the abundance of 
each ion, with a different m/z value, is registered and measured by the detector. The detector is 
connected to a computer which displays the result as a mass spectrum. MS coupled to liquid 
chromatography (LC) is abbreviated to LC-MS. A major advantage of coupling MS to LC is 
the ability to distinguish different substances with similar retention times, as well as separating 
different compounds with exact same m/z value (36).   
 
Figure 1-3 Schematic view of LC-MS. 
1.7.1 Electrospray Ionization 
In the electrospray ionization (ESI) interface, the sample constituents are delivered in a volatile 
mobile phase from the LC system and passes through a narrow capillary producing a fine 
aerosol by nitrogen gas flowing along the capillary. An electrode is placed in continuation of 
the capillary, coupling an electrical potential between the capillary tip and electrode. This 
transfers the electrical potential to the small drops in the aerosol, resulting in a fine aerosol of 
charged droplets. The liquid droplets evaporate and are flushed away by a drying gas. When 
the solvent evaporates of the droplets there are two forces becoming dominant, surface tension 
in the droplets acting to retain the shape and Coulomb force of repulsion between like charges 
acting to break down the shape of the droplet. As the solvent evaporates the droplet size 
decreases and at one point the Coulomb force of repulsion overcome the surface tension and a 
Coulomb explosion occurs. The droplets disintegrate into much smaller droplets, and the cycle 
repeats until all of the solvent has been evaporated. The analyte molecules remain charged and 






Figure 1-4 Schematic for Orbitrap ID-X MS. 
Metabolomics and lipidomics methods require the analysis of complex mixtures, detection of 
analytes of different types and over a wide range of concentrations. Consequently, there is a 
need for instruments with better resolution, mass accuracy and tandem mass spectrometry 
(MS/MS) capabilities. For identification, the use of high-resolution MS (HR-MS) provides 
accurate mass determinations with four or five decimals. HR-MS can determine the elemental 
composition of both molecular ions and fragment ions by combining accurate mass 
determination with search in different data bases, suggestions for elemental composition, 
structure formulas and in some cases fragmentation patterns when available (36).  
The Orbitrap is the youngest member of the family of mass spectrometers. The Orbitrap mass 
analyzer consists of a solid, spindle-like central electrode that is placed within an outer barrel-
like electrode and is a few centimeters in length. In the space between the two electrodes, 
trapped ions undergo complex oscillations and high-resolution measurements take place. Due 
to the unique geometric shape of the electrodes, the ions not only rotate at a given orbit around 
the central electrode, but also produce an axial oscillation along the length of the electrode. The 
axial oscillation frequency depends entirely on the mass/charge (m/z) ratio of the ion. The 
orbitrap measures the frequency and the intensity of the oscillating ions. The Orbitraps mass 
resolving power is directly proportional to the measurement time, as it may take thousands of 




resolving power comes at the price of longer measurement times. This also results in fewer 
available datapoints across a chromatographic peak (38).  
The ability of the C-trap in the Orbitrap to accumulate ions is one relevant difference that 
separates the Orbitrap from the conventional triple quadrupole (QqQ) and time of flight (Q-
TOF) instruments. The Orbitrap mass analyzer must maintain a low-pressure environment to 
minimize the collision of oscillating ions with residual gas molecules as much as possible. As 
the ions have to be accelerated from a high-pressure area to a low-pressure area, the fast 
injection of a very dense ion cloud is required. The C-trap is able to collect and store ions, and 
also accelerating the ions into the mass analyzer through a small opening. In addition to this, 
the increase of the voltage of the central electrode to bend the ion trajectories is essential to 
enable successful trapping of the ions in the mass analyzer (38).  
The fragmentation in the Orbitrap can be done in the high energy collision dissociation (HCD) 
cell or by collision induced dissociation in the CID cell. Fragmentation with residual nitrogen 
gas occurs when ions are accelerated from the C-trap into the HCD cell. The fragments are 
returned from the HCD cell as a single ion cloud into the C-trap. In CID collision, the ions are 
first collected as a package and thereafter moved by resonance back and forth in a collision gas 
until the ions break apart and produce fragments. The Orbitrap also contains a quadrupole that 
often serves as a broadband mass filter to reduce total ion abundance permitting longer injection 
times or to isolate the precursors for fragmentation. The quadrupole cannot be used in the scan 
mode because the Orbitrap and C-trap require ion clouds. Unlike QqQ instruments, the orbitrap 
detector does not monitor the incoming ions in a continuous manner. Instead it produces a data 
point after a sufficient number of ion oscillations in the mass analyzer has been monitored and 





1.7.3 AcquireX Methodology 
AcquireX acquisition is an attractive strategy to acquire quantitative, complete MS data from 
the full scan data, as well as confirmation data from the MS/MS data (38). AcquireX requires 
an exclusion list, i.e. compounds present in a blank sample, and an inclusion list, i.e. compounds 
present in a representative sample. In AcquireX mode, the MS instrument performs a full scan, 
followed by MS/MS analysis on precursor ions selected from the inclusion list. When MS/MS 
data of the representative sample is available, it is aligned with the full scans of the samples by 
m/z and retention time. The selection of precursor ions for MS/MS analysis is dependent on the 
intensity of the ion. Thus, compounds with low abundance may not be selected for 





2 Aims of the Thesis 
The overall aim of this study is to develop a sample processing methodology for simultaneous 
extraction of lipids and metabolites from the same sample. The methodology will afterwards 
be used to explore the differences in the lipidome between people taking high dose vitamin D 
compared to placebo. In addition, the differences in the autumn compared to in the spring is 










3 Materials and Methods 
3.1 Materials  
3.1.1 Chemicals 
Table 3-1 List of chemicals 
Chemical CAS Manufacturer 
Methanol 67-56-1 Sigma-Aldrich 
Methyl-tert-butyl-ether 1634-04-4 VWR International 
Chloroform  67-66-3 Supelco  
2-propanol  67-63-0 Supelco  
Acetonitrile 75-05-8 VWR International 
Ammonium formate  540-69-2 Supelco 
Formic acid 64-18-6 Supelco 
3.1.2 Materials and Equipment  
Table 3-2 List of materials and equipment 
Material/Equipment Description Manufacturer/Provider 
Thermo Scientific™ 
Orbitrap IdX™ Tribrid™ 
MS-instrument Thermo Fisher Scientific 
Thermo Scientific™ 
Vanquish™ 
UPLC-system Thermo Fisher Scientific 
Acquity™ Premier BEH 
C18 1.7 µm, 2.1 x 100 mm 
Column Waters 
MagNA Lyser Instrument Cell lysis instrument Roche  
Biofuge fresco Refrigerated centrifuge Heraeus Instruments 
Heidolph Reax top Vortex Heidolph Instruments 
Stuart sample concentrator 
SBHCONC/1 
Evaporator/concentrator 
with N2   
Cole-Parmer 








CentriVap Concentrator Evaporator/concentrator 
with centrifugal force, 
vacuum, and heat 
Labconco 
M-pact AX423 Scale Sartorius Mechatronics  
MagNA Lyser Green Beads Vial and beads for cell lysis Roche  
Eppendorf tubes Safe-Lock Tubes 1.5 ml Eppendorf Research  
HPLC vial 12x32 mm glass screw neck 
vial, cap, nonslit 
PTFE/silicone septa, Total 
Recovery 
Waters 
HPLC vial 12x32 mm glass screw neck 
vial, cap, nonslit 
PTFE/silicone septa 
Waters 





Pipette tip 10 µl 
250 µl 
1000 µl 
Thermo Fisher Scientific 
Laboratory bottles, round Borosilicate 3.3 glass, with 






Puranity PU 15 System Ultrapure water system, 







3.2 Study Design and Methods 
3.2.1 Study Population and Recruitment  
This study included healthy subject with serum 25(OH)D levels in the range 25-45 nmol/L. The 
participating subjects had either participated in previous vitamin D intervention studies 
performed by the research group or were recruited through advertisements in the local press 
and on billboards at UiT – the Arctic University of Norway and the University Hospital of 
North Norway (UNN) in Tromsø. Those who responded were contacted by phone by a study 
nurse and informed about the study. If they were still interested in participating after being 
informed about the study and there were no contradictions in their medical history, an 
appointment for the first visit was made. The consent form sent by mail as further information.  
The study only included men between the age of 20 to 70 years and postmenopausal women 
over 60 years with BMI in the range 21-32 kg/m2. Exclusion criteria were smoking, use of 
medication, use of vitamin D supplements or cod liver oil, vacation in a sunny country or use 
of solarium during the study period, development of any chronic disease and start of permanent 
or long lasting medication, dieting or new vigorous exercise/training, allergy to nuts or local 
anesthetics, disturbances of calcium metabolism (primary hyperparathyroidism), 
granulomatous diseases (Wegner’s granulomatosis, sarcoidosis, tuberculosis), reduced kidney 
function (creatinine >115 µmol/L in males and 110 µmol/L in females), and renal stones in the 
last 15 years.  
3.2.2 Intervention 
The intervention was performed for two months during the time of the year with the lowest 
serum 25(OH)D levels. The inclusion period was from October until January and the last visits 
by the end of March. Subjects randomized to treatment group each received one box with 24 
vitamin D3 capsules (20 000 IU). Correspondingly, subjects of the placebo group each received 
a box with 24 identically looking placebo capsules. Directly after baseline procedures, the 
subjects were to take four capsules as a loading dose. Afterwards, two capsules were to be taken 
each week with the exception of the last day before the last visit. The subjects were contacted 
by phone after one month. The purpose was mainly to remind the subject to take the medication, 





Randomization to the vitamin D or placebo group was performed using a block randomization 
procedure and stratified according to gender and BMI (<27 kg/m2 and >27 kg/m2). 
Randomization was performed by the central randomization unit at the Clinical Research 
Center, University hospital of North Norway, which was informed of about gender, BMI and 
date for baseline visit after the screening by the study nurse.  
The randomization numbers with treatment allocations were provided directly to the hospital 
pharmacy where the medication was prepared. The participants received the study medication 
at the end of the baseline visit. Only the pharmacy and the Clinical Research unit at the hospital 
had access to the randomization list. All investigators were kept blinded. All data were sent 
directly to the hospital’s Clinical Research unit where they were merged and coupled to the 
randomization code. The final file without person identification was then sent to the principal 
investigators.  
3.2.4 Samples 
After blood samples for analysis of background characteristics were taken in fasting state, and 
15 minutes rest, fat biopsies were taken from the SAT on the lower abdomen according to the 
procedure described by Mutch et al. (39), washed with phosphate buffered saline, immediately 
frozen in liquid nitrogen and stored at -80 ºC.  
The participants were assigned an ID number which the samples were marked with either visit 
2 (v2) or visit 3 (v3) for whether it was taken at baseline or endpoint, respectively. List of all 
samples can be found in the appendix.  
3.2.5 Sample Preparation 
The method used was taken from Matyash’s (40) solvent extraction method with the use of 
Methyl-tert-butyl ether (MTBE) and Coman’s (41) Simultaneous Metabolite Protein Lipid 
Extraction (SIMPLEX) method, with some slight modifications. As the method was going to 
be utilizing MagNA Lyser Green Beads to homogenize the sample, it was advantageous to be 
have the organic phase containing the lipids as the upper phase of the two-phase partitioning 
system like in Matyash’s (40) extraction with the use of MTBE. This simplifies the sample 
handling. Metabolites were extracted from the remaining aqueous phase in the Green Beads 
tube. This was done with a SIMPLEX method, where both lipids and metabolites can be 




difficult to collect. It was for that reason decided to use chloroform which has a higher density. 
This way the aqueous phase will form the upper phase and end up above the beads, while the 
new organic phase consisting of chloroform will form the lower phase. Thus, the metabolites 
can be easily collected.  
 
Figure 3-1 Workflow of sample preparation. Created with BioRender.com 
3.2.5.1 Optimizing Method of Sample Preparation 
The lipids were first tried extracted from fat biopsy by adding 700 µl of a mixture of MeOH 
and MTBE in 1:1 ratio and homogenized with MagNA Lyser Green Beads at 7 000 rpm for 30 
seconds. 300 µl of Milli-Q water was then added to induce phase separation, though this did 
not work as planned. There was no visible phase separation at this point. Different ratios of the 
solutions were then tried to find the ratio that would give a visible phase separation that is also 
above the ceramic beads. From the results it was concluded that the ratio in which gave a visible 
phase separation was MTBE/MeOH/water in the ratio 7/3/2.5 v/v/v.  
It was then decided to try three different methods, method A, B and C, to find out whether 
adding MTBE, MeOH and water in different steps is better that adding all simultaneously in 
one step. Method A added only MeOH before going through cell lysis in the MagNA Lyser, 
before adding MTBE and then water at last. Method B added both MeOH and MTBE before 
cell lysis, and then water for phase separation. Method C added all three in one step. After 
conducting this trial, it was decided to work with method B. Which showed a slightly elevated 
amount of extracted lipids compared to method C when compared in in Lipid Search. The 




solution that could not be removed with centrifugation. Thus, the sample could not be injected 
into the HPLC and was disregarded.  
When running a full scan of the lipid samples in the orbitrap, the sample seemed to be very 
concentrated upon examination of the chromatogram. The sample was therefore diluted 1:10 
and 1:100 for comparison. By examining both high intensity areas and low intensity areas, and 
comparing the undiluted sample, 1:10 and 1:100, it was determined that a 1:10 dilution seemed 
appropriate. During the period it was discovered contamination of polysiloxanes in the samples. 
From there on it was decided to have small bottles for the working solutions. The bottles were 
washed with MeOH and refilled with new solution every week, to lessen the risk of 
contaminations.  
After extracting the lipids, the metabolites were to be extracted from the remaining aqueous 
phase in the Green Beads tube. By adding chloroform, the aqueous phase, that previously 
formed the lower phase, became the upper phase. This would ease the collection of the aqueous 
phase. After chloroform was added, it was found that the aqueous phase was very small, thus it 
was difficult to collect without possibly leaving a large amount of metabolites behind. It was 
then decided to add 200 µl of water. This made it possible to collect 400 µl from the aqueous 
phase. Though when the solvent was to be evaporated, water proved to be difficult to evaporate 
and very time-consuming. Consequently, half of the water was substituted with MeOH. This 
resulted in almost halving the evaporation time.  
After evaporation the metabolites were reconstituted in 50 µl of a 20% MeOH solution, and 
analyzed on HPLC-MS, with a reverse phase column. But after attempting to identify the 
compounds through the software Compound Discoverer it was discovered that many of the 
compounds had up to 5 duplicates with different retention times, which was not ideal. Assuming 
this was caused by poor separation in the column, it was attempted to reduce the concentration 
of MeOH in the sample vial to 5%. The number of duplicates was reduced to 2 copies of the 
same compound for some compounds, and 3 for a very few, though there were no visible 





Figure 3-2 Workflow of final sample preparation with optimized volumes. Created with BioRender.com 
3.2.5.2 Lipid extraction 
The fat biopsy samples were prepared using solvent extraction with the use of MagNA Lyser 
Green Beads to homogenize the solid sample. 15 mg of sample was weighed out into the Green 
Beads tubes. In the tubes, 300 µl MeOH and 700 µl MTBE was added and then oscillated in 
the MagNA Lyser instrument at 7000 rpm for 30 seconds. 250 µl water was then added to 
induce phase separation. The tube was then shaken vigorously before centrifuged at 13 000 rpm 
(16 060 g) for 5 minutes. 600 µl of the upper layer of MTBE containing the lipids was then 
extracted from the tube into a vial. 60 µl, corresponding to 10%, of the organic phase was 
transferred to a total recovery vial where the solvent was evaporated (55ºC, N2) and 
reconstituted in 200 µl isopropanol.  
3.2.5.3 Metabolite extraction 
Metabolites are extracted from the remaining aqueous phase in the Green Beads tube. 500 µl 
chloroform was added to form the new organic phase, which because of the density will become 
the lower phase in the two-phase partitioning system. 100 µl water and 100 µl MeOH was added 
to increase the volume of the aqueous phase. The tube was vortexed for 20 seconds, and then 
centrifuged at 13 000 rpm (16 060 g), for 5 minutes. 400 µl of the aqueous phase, which now 
forms the upper phase, was collected into an Eppendorf tube. The solvent was then evaporated 
(50ºC, centrifugal force, vacuum), reconstituted in 50 µl of a 5% MeOH solution and transferred 





The reproducibility of the sample preparation was tested by preparing 6 samples with the 
method distributed over 3 days, in other words, 2 samples each day. For the lipids, it was only 
performed full scans for each sample. Masses of 20 different lipids were randomly picked out, 
where 10 were of high intensity and 10 were of low intensity. The intensity of each of the 20 
lipids in the samples was compared and standard deviation was calculated. As for the 
metabolites a short AcquireX, DDA, with 3 deep scans was performed and data processed in 
Compound Discoverer.  
3.2.6 HPLC-MS  
The HPLC-MS analysis was performed with a Thermo Scientific™ Orbitrap IdX™ Tribrid™ 
Mass Spectrometer, connected to a Thermo Scientific™ Vanquish™ UHPLC.  
3.2.6.1 Lipid analysis 
The UHPLC utilized an Acquity™ Premier BEH C18 column (1.7 µm, 2.1 x 100mm), and a 
binary gradient (solvent A: 50% ACN, 1 mM NH4FA, 0.01% FA, solvent B: 50/50 IPA/ACN, 
1 mM NH4FA, 0.01% FA) of 30 minutes, with a flow rate of 0.6 ml/min and at 60 ºC.  
Table 3-3 UHPLC gradient for the analysis of the lipidome 
Time (minutes) Flow (ml/min) %A % B 
-3.0 Equilibration 
-3.0 0.6 70 30 
0.0 0.6 70 30 
0.0 Run 
0.0 0.6 70 30 
20.0 0.6 25 75 
25.0 0.6 5 95 







Table 3-4 Orbitrap IdX™ Tribrid™ settings for the analysis of the lipidome 
MS Global settings  
Method Duration (min) 30 
Expected LC peak width (s)  3 
Data dependent mode Cycle time  
Cycle time (s) 1.5  
MS OT  
Orbitrap resolution  120 000 
Scan range (m/z) 250-1500  
AGC target 400 000  
Maximum injection time (ms) 50 
Polarity  Positive 
ddMS2 OT HCD  
Collision energy mode Stepped 
Collision energies (%) 25, 30, 35 
Orbitrap resolution 15 000 
Maximum injection time (ms) 50 
AGC target 50 000 
ddMS2 OT CID   
Collision energy mode Fixed 
Collision energy (%) 32 
CID activation time (ms) 10 
Orbitrap resolution 15 000 
Maximum injection time (ms) 50 
AGC target 50 000 
ddMS3 OT CID  
Collision energy mode Fixed 
Collision energy (%) 35 
Activation time (ms) 10 
Activation Q 0.25 
Orbitrap resolution 15 000 
Maximum injection time (ms) 65 




3.2.6.2 Metabolite analysis 
The UHPLC utilized an Acquity™ Premier BEH C18 column (1.7 µm, 2.1 x 100mm), and a 
binary gradient (solvent A: H2O, 1 mM NH4FA, 0.01% FA, solvent B: 50/50 IPA/ACN, 1 mM 
NH4FA, 0.01% FA) of 16 minutes, with a flow rate of 0.5 ml/min and at 60 ºC.  
Table 3-5 UHPLC gradient for the analysis of the metabolome 
Time (minutes) Flow (ml/min) %A % B 
-2.0 Equilibration 
-2.0 0.5 99.5 0.5 
0.0 0.5 99.5 0.5 
0.0 Run 
0.0 0.5 99.5 0.5 
1.0 0.5 99.5 0.5 
15.0 0.5 5 95 
16.0 0.5 5 95 
16.0 Stop Run 
 
MS-settings: 
Table 3-6 Orbitrap IdX™ Tribrid™ settings for the analysis of the metabolome 
MS Global settings Positive Negative 
Method Duration (min) 16 15 
Expected LC peak width (s)  3 3 
Data dependent mode Cycle time  Cycle time  
Cycle time (s) 0.6 0.6 
MS OT   
Orbitrap resolution  60 000 60 000 
Scan range (m/z) 70-800 70-800 
AGC target 100 000 100 000 
Maximum injection time (ms) 50 50 
Polarity  Positive  Negative 
ddMS2 OT HCD   
Collision energy mode Stepped Stepped 
Collision energies (%) 20, 35, 50 20, 35, 50 
Orbitrap resolution 30 000 30 000 
Maximum injection time (ms) 54 54 





3.2.7 AcquireX  
Figure 3-3 Schematic view of the AcquireX setup 
The AcquireX run was started with 5 full scans of the blank sample where the last was used to 
create an exclusion list. Then a full scan of a representative sample (RS), consisting of 4 µl of 
30 different samples, to create an inclusion list. Then followed by 5 deep scans of RS for 
identification with MS/MS. Thereafter, full scans of RS once, then 10 samples, followed by a 
blank and RS twice, before another 10 samples and repeating this cycle until all samples are 
injected. Before starting the AcquireX run, 2 blanks and 2 RS was run to equilibrate and as a 
control.  
The time the samples were in the autosampler were minimized by changing out the samples 
twice a day, every 8-16 hours. Already injected samples were placed back into -80 ºC, and new 
samples were taken out and put into the autosampler. This was to reduce the risk of any 
alteration of the lipidome. RS and blank sample were in the autosampler for the duration of the 
entire run of approximately 80 hours.  
The reproducibility of the AcquireX was tested by applying the masses of the same 20 lipids 
earlier used for the same purpose, into Skyline. Skyline registered the mass accuracy, retention 
time and peak area of each lipid in each of the RS, and generating simple graphs displaying the 





3.2.8 Data Analysis 
The analysis of the data was performed using the software LipidSearch™ and Compound 
Discoverer™ for lipids and metabolites respectively for identification and quantification. 
Multivariate data analysis and other analyses was performed using SIMCA® software and 
MetaboAnalyst.  
3.2.8.1 LipidSearch™ 
LipidSearch software processes LC-MS data to provide accurate lipid identification by aligning 
the peaks of the full scan of the samples and MS/MS data of the RS, and then integrates the 
peaks for relative quantification. The database contains defined structures and includes more 
than 1.5 million lipid ions and their predicted fragment ions (42).  
Retention time tolerance was set to 0.2 minutes. LipidSearch has some problems integrating 
the peak area for compounds when the chromatographic peaks are not perfect, often integrating 
only a small corner or half of the peak. The integration for each lipid was looked over and 
manually integrated where it was necessary. Data was exported into an excel file.  
3.2.8.2 SIMCA® 
SIMCA Multivariate Data Analysis software is a data analytics tool used to gain information 
from large quantities of data. Multivariate data analysis analyzes multiple variables 
simultaneously and comprehend how various parameters interact with each other (43). Data 
generated in LipidSearch was imported into SIMCA which was used to perform principle 
component analysis (PCA), partial least squares discriminant analysis (PLS) and orthogonal 
partial least squares (OPLS). The analyses were first performed with the unprocessed dataset, 
with the peak area of the lipids as x-variable. PLS and OPLS was done with group affiliation 
(placebo baseline, placebo endpoint, vitamin D baseline and vitamin D endpoint), serum 
25(OH)D level and SAT vitamin D level, as well as the ratios (endpoint/baseline) of the latter 
two as discriminant criteria. The peak areas were then calculated into ratios and a new PCA, 
PLS and OPLS was performed, with group affiliation, serum 25(OH)D ratio and SAT vitamin 
D ratio as discriminant criteria. In SIMCA, data was scaled with pareto scaling (mean-centered 
and divided by the square root of the standard deviation of each variable) and no normalizations 




3.2.8.3 MetaboAnalyst  
MetaboAnalyst is a comprehensive web-based platform dedicated for metabolomics data 
analysis. The objective is to enable high-throughput analysis for both targeted and untargeted 
metabolomics (44). MetaboAnalyst was used to perform statistical analyses, biomarker 
analysis, enrichment analysis as well as pathway analysis.  
Statistical analysis module in MetaboAnalyst includes PCA, PLS and OPLS as well as other 
commonly used statistical methods. The discriminant criterion in PLS and OPLS in 
MetaboAnalyst is limited to being categorical. Therefore, only group affiliation was used as 
discriminant criterion in PLS and OPLS performed in MetaboAnalyst. Enrichment analysis and 
pathway analysis was performed to identify biologically meaningful patterns that are 
significantly enriched and to help identify the most relevant pathways involved in the conditions 
of this study. Biomarker analysis was performed for the 10 most influential lipids in the OPLS 
performed in SIMCA. This analysis provides the receiver operating characteristic (ROC) curve-
based approach to identify potential biomarkers and evaluating their performance. In all 
analyses, the data was normalized by a pooled or average sample from the placebo group, 








4 Results and Discussion 
4.1 Sample Preparation 
By extracting lipids and metabolites from the same sample, the amount of required sample is 
reduced, and sample handling errors reduced by fewer extraction steps. Thus, saving valuable 
sample material and enabling additional analyses, thereby gaining more information per 
sample. Though there are limitations for this method of extracting. Certain low abundance or 
very hydrophilic lipids will be hard to detect and may escape the hydrophobic phase. Similar 
behavior is likely for amphiphilic metabolites. This would be a disadvantage of the use of 
chloroform. Though chloroform would help remove any extra lipids that MTBE was not able 
to extract form the metabolite fraction, it could cause loss of unique compounds that would be 
removed from both lipid fraction and metabolite fraction. In such cases, an additional re-
extraction would be beneficial. 
The original Matyash (40) method of extraction operated was with the solvent ratios 10/3/2.5 
v/v/v MTBE/MeOH/water. In this thesis the solvent ratio used was 7/3/2.5 v/v/v. It was first 
attempted with a ratio of 3.5/3.5/3 v/v/v, which would be similar to the solvent ratio of Bligh 
and Dyer’s (45) extraction method of 2/2/1.8 v/v/v CHCl3/MeOH/water. A study (46) 
comparing a similar solvent ratio to the original Matyash method and the conventional Bligh 
and Dyer across plasma, urine, and model organism D. magna. The study showed that their 
modified Matyash method had higher or comparable extraction yield and reproducibility than 
the original Matyash and Bligh and Dyer (46). When the similar solvent ratio of 3.5/3.5/3 v/v/v 
was attempted with adipose tissue samples in this thesis, the phase separation was not visible. 
For the sample of adipose tissue homogenization was needed, and the method applied in the 
thesis was with the use of MagNA Lyser Green Beads. As this method utilizes rigorous shaking 
with the ceramic beads, it may have leaded to the formation of an emulsion and thus no phase 
separation was found. Therefore, the solvent ratio used was 7/3/2.5 v/v/v. As there was a limited 
volume in the MagNA Lyser Green Beads tubes, as well as a minimum amount of water to 
cover all of the beads, the solvent ratio of the original Matyash method was not suitable with 
the use of MagNA Lyser Green Beads. 
When testing different procedures for sample extraction, method A did not give the desirable 
results as it could not be analyzed because of the insoluble particles dispersed in the sample. A 
possible reason for this may be the small volume of liquid in the tube during the homogenizing, 




rigorous oscillations, but without liquid it might be difficult to properly do so. The samples 
from both method B and C were homogenized and resulted in clear samples without particles. 
When comparing both in LipidSearch™ method B showed higher levels of extracted lipids than 
method C in all lipid classes except the glycerolipids where the levels were the same in both 
methods if not slightly higher in method C, figure 4-1. The difference between method B and 
C was whether water was added before or after homogenizing. It seems as though having water 
present during homogenization may cause less lipids to be extracted than when there is only 
organic solvents present, since lipids are poorly soluble in water.  
 
Figure 4-1 Class profile. Peak areas of the lipid classes LPC, LPE, PE, PS, DG, PC and TG, for method B and method C. 
Green=Method B, Blue=Method C.  
Contamination of polysiloxanes found during the optimization of the sample preparation 
procedure was found in all samples, but in fluctuating intensities. After extended testing, it was 
later found that the intensity of the polysiloxanes signals increased with each repeating injection 
from the same vial. Subsequently, it was concluded that the polysiloxanes came from the caps 
of the vials. Each time the needle penetrates the septa it brings the polysiloxanes into the sample 
and accumulates for each injection, thus increasing the signal. The contamination was less with 
pre-slit caps, but for this experiment nonslit was necessary due to the possible evaporation of 
solvents from the vials. In addition, the contamination was of less importance when running an 
AcquireX method as the polysiloxanes would be excluded as it is present in the blank sample 




block for other more important ions that could have been analyzed. Additionally, this was only 
observed for the lipid samples and not in the metabolite samples. This seems to be explained 
by the solvents used for these samples. While the lipids are dissolved in the organic solvent 
IPA, the metabolites are dissolved in mostly water. IPA is able to dissolve the polysiloxanes 
the needle drags with it into the sample, while water is not able to. This way, polysiloxanes are 
able to accumulate in the lipid samples and not in the metabolite samples. 
When testing the reproducibility of the method for sample preparation the intensity of the 
masses of 20 randomly picked lipids were noted for 6 samples prepared on 3 separate days, 2 
samples each day. The result showed that the relative standard deviation (RSD) of the intensity 
of the lipids was 30% on average, though it varied from 8-78%. Lower intensity lipids showed 
a trend of higher RSD, while the high intensity lipids generally showed lower RSD. This was 
to be expected since when the intensity of the lipid is low, even small variations will result in 
high RSD. While for the high intensity lipids, big variation may not result in high RSD. Lipids 
extracted on day 1 seems to have a slightly higher intensity than that of day 2 and day 3. 
Table 4-1 Intensity of 20 lipids from 6 samples, with calculated standard deviation. Red highlight shows sample with the 
highest intensity of the lipid, green highlight shows the lowest.  
 Day 1 Day 2 Day 3     






TG 18:1 18:1 18:0 8.64E+08 8.30E+08 6.11E+08 6.51E+08 6.46E+08 6.62E+08 7.11E+08 107513100 15 % 
TG 16:1 18:2 18:1  9.28E+08 9.01E+08 7.36E+08 7.59E+08 6.99E+08 7.49E+08 7.95E+08 94903459.72 12 % 
TG 18:1 18:1 16:0 7.56E+08 8.07E+08 6.49E+08 6.93E+08 7.48E+08 6.93E+08 7.24E+08 56630969.15 8 % 
TG 16:1 16:1 18:1  8.96E+08 8.49E+08 6.48E+08 6.55E+08 6.61E+08 6.76E+08 7.31E+08 111120505.2 15 % 
TG 16:1 14:1 18:1 4.64E+08 4.47E+08 4.16E+08 3.10E+08 2.59E+08 2.62E+08 3.60E+08 93621934.75 26 % 
TG 20:1 18:1 18:0 1.79E+08 1.91E+08 1.23E+08 1.41E+08 9.48E+07 8.24E+07 1.35E+08 43896605.79 32 % 
TG 18:0 18:1 16:0 3.98E+08 4.16E+08 3.24E+08 3.35E+08 3.13E+08 2.98E+08 3.47E+08 48148381.77 14 % 
PC 18:1 18:3 1.45E+06 1.08E+06 5.97E+05 6.77E+05 7.11E+05 8.88E+05 9.01E+05 320094.2049 36 % 
DG 36:3e 1.85E+07 1.65E+07 1.16E+07 1.37E+07 1.24E+07 1.24E+07 1.42E+07 2730140.412 19 % 
PC 16:0 18:2  3.73E+06 3.13E+06 1.84E+06 2.10E+06 2.20E+06 2.78E+06 2.63E+06 717272.6121 27 % 
PC 16:0 18:1 6.90E+06 5.15E+06 3.28E+06 3.75E+06 3.92E+06 4.93E+06 4.66E+06 1312291.888 28 % 
DG 36:4e 2.33E+07 2.37E+07 1.47E+07 1.74E+07 1.70E+07 1.67E+07 1.88E+07 3759787.228 20 % 
LPC 16:0   1.21E+06 6.88E+05 1.08E+06 7.77E+05 1.62E+06 2.76E+06 1.36E+06 764181.7628 56 % 
PC 16:0 16:1 1.45E+06 1.20E+06 6.48E+05 7.30E+05 9.06E+05 1.12E+06 1.01E+06 303991.4472 30 % 
DG 1:16 4:20 1.60E+06 1.55E+06 9.72E+05 1.09E+06 7.54E+05 6.61E+05 1.10E+06 395297.2299 36 % 
LPC 18:1  2.87E+05 1.76E+05 3.58E+05 2.66E+05 5.46E+05 7.77E+05 4.02E+05 221852.8041 55 % 
LPE 16:0  9.46E+04 5.87E+04 6.54E+04 5.91E+04 1.44E+05 3.02E+05 1.21E+05 94647.14822 78 % 
DG 18:2 18:2 4.65E+04 5.67E+04 4.13E+04 4.71E+04 3.50E+04 3.70E+04 4.39E+04 7929.859183 18 % 
DG 18:0 22:5 1.76E+04 1.86E+04 1.21E+04 1.70E+04 1.16E+04 1.41E+04 1.52E+04 2977.694858 20 % 
LPE 18:2 8.09E+03 6.61E+03 1.46E+04 1.97E+04 1.62E+04 3.26E+04 1.63E+04 9396.277987 58 %          
Average 




Correspondingly, 6 metabolite samples were prepared, 2 samples each day for 3 days. 
Reproducibility of the extraction of metabolites were tested by performing a short AcquireX 
and data processed in Compound Discoverer 3.1. The data showed good reproducibility of the 




between the days when the p-value had been adjusted using Benjamin-Hochberg correction for 
the false discovery rate. Results showed that the RSD of the area of the metabolites was on 
average 32%, though it varied from 2-108%. Only 4 out of 285 metabolites had an RSD over 
100%. The metabolites also indicate a trend of higher RSD in lower intensity metabolites, and 
lower RSD in higher intensity metabolites, like seen in lipids. 
 
Figure 4-2 Box plot of area under the peak for all metabolites in 6 samples.  
Metabolite identification was not optimized in the current project and it was decided to not 
include the metabolites in the current project due to time limitations and dependency of other 
larger projects to establish standardized LC conditions for both reverse phase and HILIC 
chromatography. Prepared metabolite fractions are stored at -80ºC awaiting instrument method 






When testing the reproducibility of the AcquireX run, the results showed that mass accuracy 
was mostly at an adequate level, although one of the lipids had a mass error almost reaching 3 
ppm. However, a large shift in retention time where the trend showed a decrease in retention 
time from the first sample to the last was observed, figure 4-3. At the best the decrease in 
retention time from start to end was 0.5 minutes, but at worst the difference was at 3.4 minutes. 
At the same time, the pressure also decreased with the same trend as the retention time, where 
the pressure had decreased from 667 bar in the first RS full scan to 608 bar in the last. Therefore, 
it was suspected that it was either a problem with the pump or there was a leakage. Through 
further investigation it was found that there was a leakage of mobile phase A. This led to an 
increase in percentage of mobile phase B which caused the decrease of retention time. Thus, 
causing the compound to elute earlier each run.  
 
Figure 4-3 Retention time profile of the first AcquireX run. A: TG 18:1 18:1 16:0, B: PC 16:0 18:2, C: DG 18:2 18:2. Generated 
with Skyline. 
This caused a problem when analyzing the data with LipidSearch™. Since the retention time 
differed greatly, LipidSearch™ was not able to align the sample data with the MS/MS data and 
therefore not able to identify and quantify the compounds. For this reason, it was necessary to 
redo the AcquireX run after the leakage was repaired. At the second attempt, the stability had 







Figure 4-4 Retention time profile of the second AcquireX run. A: TG 18:1 18:1 16:0, B: PC 16:0 18:2, C: DG 18:2 18:2. 
Generated with Skyline. 
The peak area was adequately reproduced throughout the run with the exception of the last five 
RS that had an increase in peak area. The suspected cause for the increase is that the vial with 
the RS had been vortexed once as it was observed precipitation at the bottom of the vial. The 
time of the vortexing matches that of the observed change in peak area. The increase was most 
prominent in PCs and less prominent in the TGs, which can possibly be attributed to the 
abundancy of the TGs compared to the other lipid classes or simply the different properties of 
the lipids. 
Though it is unknown whether it was lipids that precipitated, it would be reasonable that mixing 
the RS cause possibly precipitated lipids to dissolve back into the sample and thereby increasing 
concentration and peak area. Precipitation was not observed for the samples, nor the blank 
sample. The RS is the only sample containing lipids that is in the autosampler at 5ºC for the 
entire run of more than 80 hours and is injected repeatedly at a total of 28 times. Whereas the 
other samples stay in the autosampler for maximum 16 hours and injected only once. It was 




whether the samples could be in 5ºC as this was preferred over 20ºC for the convenience for 
the many users of the orbitrap. An equivalent lipid sample was placed in 5ºC for 30 minutes 
and no precipitation was observed. Compared to the 80 hours the RS was kept in the 
autosampler, 30 minutes is a short time. Therefore, this test may not be representative for the 
experiment. For this reason, it may have been more advantageous to aliquot the RS and changed 
out together with the samples.  
The peak area did not show any substantial decrease even supposing that the lipids precipitated 
midway, and it is therefore uncertain whether the precipitation consisted of lipids. The 
evaporation of IPA was tested before, where 1% of IPA evaporated in 24 hours. This was tested 
with a vial of IPA left in the autosampler for 24 hours, the vial was capped with a nonslit cap 
that had been penetrated once. It may have been possible that the evaporation and precipitation 
happened at the same pace and thus keeping a constant concentration. Alternatively, the lipids 
could have been sticking to the side of the vial as IPA evaporated, keeping a constant 
concentration in the sample. In this case, vortexing would dissolve the lipids on the side of the 
vial into the sample again and thereby increasing the concentration. The increase would then 
be more prominent in lipids with higher affinity to the glass as there will be more of these 
against the glass wall of the vial.  
 





The majority had a mass error that stayed below 2 ppm, with a few exceptions where the 
highest mass error did not surpass 3 ppm. 
 
Figure 4-6 Mass errors of the second AcquireX run. A: TG 18:1 18:1 16:0, B: PC 16:0 18:2, C: DG 18:2 18:2. Generated 





4.3 Identification and Quantification 
As LipidSearch does not optimally integrate peaks that are not chromatographically perfect, it 
causes for the quantification to be inaccurate.  When integrating the peak area for the same 
compound, one of the samples may only have half of the peak integrated while another has the 
whole peak integrated, figure 4-7. As a result, some samples may be perceived as having much 
lower intensity of a compound than they actually do and cannot represent the reality. Therefore, 
the data could not be used as it was and needed to be processed. The reintegration was done to 
the best ability with the time available. Ideally, each sample should be integrated separately for 
the best accuracy, but due to time constriction this was not possible. Therefore, all samples 
were reintegrated as a bulk for each compound, with a few exceptions. Since the retention time 
did not vary, this was unproblematic most of the time.   
 
Figure 4-7 Integration of TG 14:0 18:2 15:0 in LipidSearch. A: All samples integrated by LipidSearch. B: All samples manually 
integrated. C: 5 of the samples integrated by LipidSearch. D: 5 of the samples manually integrated. 
The retention time tolerance for the alignment in LipidSearch was set to be 0.2 minutes. The 
deviation of the retention time was less than 0.1 minutes for the 20 tested lipids. In the case of 
these 20 lipids, the retention time tolerance could be set to 0.1 minutes, but because the retention 
time deviation of all the remaining lipids is unknown 0.1 minutes was added. Looking through 
the dataset there were observed duplicates for some of the lipids, some of which being isomers 
and some not. As an attempt to remove duplicates an alignment with the retention time tolerance 
adjusted to 0.3 minutes was run to compare. When comparing the two alignments, there were 




Consequently, it was chosen to proceed with the alignment with 0.2 minutes retention time 
tolerance. With 0.2 minutes retention time 633 lipids were identified, where 511 of these were 
triglycerides (TG), 73 phosphatidylcholines (PC), 22 phosphatidylethanolamines (PE), 18 
diglycerides (DG), 6 phosphatidylserine (PS), 2 lysophoshatidylethanolamines (LPE) and 1 
lysophosphatidylcholine (LPC).  
The identification of some of the lipids were not complete. LipidSearch would be able to define 
which lipid class as well as the total number of carbons in the fatty acid chains and number of 
double bonds, but not how these are distributed. For example, it would identify a lipid as PC 
32:2 but not be able to tell how the 32 carbons and double bonds are distributed over the two 
fatty acid chains on a PC. This lipid could for example be PC 16:1 16:1 or PC 14:0 18:2. This 
was seen in all of the lipid classes, but it was most prominent among the phosphoglycerides 
where the majority did not have the fatty acid chains identified. The reason for this is that in 
the MS/MS these lipids almost exclusively lose their phosphate head group. Taking PCs as an 
example, these showed an intense fragment at m/z 184 which is attributed to the choline 
phosphate headgroup. It might have been possible to acquire a better identification of these in 
LipidSearch by adjusting the intensity threshold. By lowering the intensity threshold, it could 
be possible to find the less intense fragments of the fatty acid chains. However, this would also 





4.4 Multivariate Data Analysis 
The omics provide a comprehensive, or global, assessment of a set of molecules and the goal 
is to determine the relative differences between two or more systems or conditions. However, 
with such global analyses with high information content, it is a challenge to efficiently form 
biologically relevant conclusions from the datasets. An approach to data interpretation in omics 
is therefore the use of multivariate data analysis (MVA), such as principal component analysis 
(PCA) and partial least squares regression analysis (PLS).  
The main objective of PCA and PLS is to identify differences between classes from a 
multivariate dataset. The aim of PCA is to achieve a linear transformation with lower 
dimensionality output data that neglects as little of the variance in the original data as possible. 
While the unsupervised nature of the PCA algorithm enables unbiased dimensionality 
reduction, it only reveals group clusters when within-group variation is sufficiently less than 
between-group variation. Therefore, supervised forms of discriminant analysis such as PLS (or 
PLS-DA) which rely on the class membership of each observation are also commonly applied 
in omics experiments. The utilization of class memberships allows the algorithm to expose the 
separation between classes better. However, variations that are not directly correlated with the 
class information is still present in the scores. This can complicate the interpretation of PLS 
scores and loading plots. Orthogonal partial least squares (OPLS) separates predictive from 
uncorrelated variation by  incorporating an orthogonal signal correction into the PLS model, 
making interpretation easier (47).  
In this study, the differences in the lipidome between the experimental groups are yet unknown. 
For exploratory studies like this, the initial application of PCA provides an informatory first 
look at the dataset structure and also the relationships between the groups. Ideally, the results 
of PCA analyses would be utilized to formulate an initial biological conclusion, which PLS or 
OPLS then can verify and test in more detail (47).  
MVA was first performed with peak area as x-variables. The results from this showed no 
separation between placebo group and vitamin D group, before and after intervention. Ideally 
the vitamin D group at endpoint should have separated from placebo baseline, endpoint, and 
vitamin D baseline. However, neither the PCA, PLS nor the OPLS showed separation between 
the groups, regardless of discrimination criterion. This could possibly be because of large 
individual differences in lipid abundancy among the participants. Therefore, the change from 




baseline to get a ratio. MVA was performed again with the ratios as x-variables. While the PCA 
displayed no separation of the samples, the groups could be distinguished from each other when 
OPLS was applied, figure 4-8.  
 
Figure 4-8 OPLS with peak area ratio (endpoint/baseline) as x-variable and group affiliation as discrimination criterion. 
Colored by group affiliation.  
This result shows that vitamin D has an effect on the lipidome in human AT. In spite of this, 
evaluating the predictive validity of the OPLS model using the Q2 values showed no 
predictability. Q2 indicates how well the model predicts new data. A large Q2 indicates good 
predictivity. Generally, a model with Q2>0.5 is regarded as a predictive model. On the other 
hand, a Q2<0 represents a lack of predictive relevance. Q2 value for this model was -0.931, 
signifying no predictivity. The reason for low Q2 value could be due to noise in the data, poor 
relationship between x- and y-variable or dominating outliers (48). 
The same analysis was done with both change in serum 25(OH)D and SAT vitamin D in the 
form of ratios as discrimination criterion. It was still not possible to discriminate the groups 
from each other in the unsupervised PCA and was only clear in the supervised OPLS. Though 
the separation of the groups was much more visible with serum 25(OH)D, than SAT vitamin D 
as discrimination criterion, figure 4-9. The model with serum 25(OH)D as discrimination 
criterion showed similarity to the model with group affiliation as discrimination criterion. 




predictability with a Q2 value of -1.16 and -0.697, for serum 25(OH)D ratio and SAT vitamin 
D ratio respectively.  
 
Figure 4-9 Supervised MVA of factors between lipid concentrations at baseline and at endpoint. A: OPLS with serum 25(OH)D 
ratio as discrimination criterion. Colored according to serum 25(OH)D ratio. B: OPLS with SAT vitamin D ratio as 
discrimination criterion. Colored according to SAT vitamin D ratio. □=Vitamin D, ○=Placebo. 
This would indicate that the relationship between lipidome and vitamin D level in AT is poorer 
than between the lipidome and 25(OH)D in serum, meaning that the lipids in AT may be 
affected not by vitamin D in AT but somewhere else. There is a possibility that vitamin D or 
25(OH)D has a mechanism of action that affects the lipids in the AT in the liver, a primary site 
of lipogenesis. 25(OH)D is the most abundant endogenous vitamin D metabolite and is 
produced in the liver. A study suggests that, even though 25(OH)D is generally considered 
biologically inactive, it acts together with 1,25(OH)2D to control lipogenesis, as the study 
identified 25(OH)D as an inhibitor of sterol regulatory element-binding protein (SREBP) 
activation, a master regulator of lipogenesis. SREBPs are transcription factors that control the 
lipid homeostasis and is majorly expressed in the liver. The activation of SREBP is regulated 
by a negative feedback loop in which sterols bind to SREBP cleavage activating protein 
(SCAP). The stability of SREBPs depends on SCAP, the escort proteins. SCAP is necessary 
for activation of SREBP. It was found that 25(OH)D mediated degradation of the SREBP-
SCAP complex is non-genomic and is independent from VDR. In addition, non-hydroxylated 
vitamin D had no effects on SCAP levels, indicating that hydroxylation is required (49).  
While investigating the dataset it was seen that there were some inconsistencies in the SAT 
vitamin D compared to what was initially expected. Comparing the SAT vitamin D levels to 
serum 25(OH)D levels, the average serum 25(OH)D level at baseline was 35.8 nmol/l and 35.3 
nmol/l in placebo and vitamin D group, respectively. At endpoint the serum 25(OH)D level 




The placebo group had a slight decrease in serum 25(OH)D, whilst the vitamin D group had an 
increase with the ratio ranging from 1.68 to 4.14 and an average at 2.9.  
On the other hand, average SAT vitamin D level at baseline was at 20.8 ng/g and 25.1 ng/g in 
placebo and vitamin D group respectively. At endpoint the average SAT vitamin D level 
remained at 20.7 ng/g in the placebo group and increased to 71.9 ng/g in the vitamin D group. 
But the level of vitamin D in AT varied greatly and a few of the individuals had a higher level 
of vitamin D at baseline than many of the individuals in the intervention group at endpoint. In 
the placebo group, the change in SAT vitamin D level was minimal, and most participants had 
a decrease in SAT vitamin D level. Though there is a visible increase in level of vitamin D in 
the intervention group from baseline to endpoint, the increase varies critically. The ratio of 
vitamin D in SAT from baseline to endpoint varied from 1.3 to 11.9 times. That would mean 
that some of the participants only had a barely increased SAT vitamin D level even after taking 
high doses of vitamin D for 2 months, meanwhile others had almost a 10-fold increase and one 
individual that had more than that, figure 4-10.  
 
Figure 4-10 Box plot of the change in serum 25(OH)D and SAT vitamin D from baseline to endpoint as a ratio 
(endpoint/baseline) in placebo and vitamin D group. 
Vitamin D is lipophilic and therefore accumulates in AT. This was demonstrated with the use 
of radioactive isotopes by Rosenstreich et al. (22). It was found that subjects supplemented with 
20 000 IU per week for 3-5 years increased vitamin D levels in SAT by approximately 6-fold 
compared with placebo. Though, the amount of vitamin D present in SAT varied substantially, 




This suggest a large individual variability due to several possible factors, such as differences in 
intake, compliance and skin production (23). A study showed that there was a relation between 
serum 25(OH)D level and SAT vitamin D level at baseline, but not after 3 months of 
supplementation of 2000 or 4000 IU/day. It was therefore suggested that adipose tissue is 
supplying vitamin D to the plasma for conversion to 25(OH)D when there is little to no recent 
vitamin D input (50). When serum 25(OH)D levels decrease after discontinuation of vitamin D 
supplement, AT vitamin D stores acquired during supplementation may be slowly released 
form AT (51). As it has been found that obese individuals have lower circulating 25(OH)D 
levels as well as attenuated UV exposure induced increase in 25(OH)D than individuals without 
obesity, it has been suggested that vitamin D is less bioavailable in obese individuals. Thus, it 
appears as though vitamin D can be trapped in AT (52). The participants in this thesis has a 
BMI between 21-32 kg/m2. A BMI of 30 kg/m2 or above is considered obese, though BMI is 
just an indication as it does not take fat and muscle percentage into consideration. It would be 
possible that the variability of vitamin D levels in AT and the poor correlation between serum 
25(OH)D and SAT vitamin D could be because of the differences in BMI. It is possible that the 
trapped vitamin D is mobilized by physical activity along with stored lipids, as physical activity 
is a strong stimulus for lipid mobilization from AT. Studies indicate that exercise has a direct 
and causal effect on 25(OH)D concentrations possibly through mobilization with lipolysis as a 
possible key mechanism (52). Therefore, another possible factor could be the individuals’ level 
of exercise. This is could not be further investigated as the individual BMI of each of the 
participants and level of physical activity was not available for this thesis. Though, fat 
percentage in the individuals may be a more interesting factor worth investigating.  
To investigate which of the lipids that was responsible for the separation between the groups, a 
variable importance for the projection (VIP) plot was generated in SIMCA. The VIP plot 





Table 4-2 List of 20 most influential lipids for OPLS model with group affiliation as discrimination criterion. 





1 TG 18:0 16:0 18:0 2.88 11.77 0.40 Increase 
2 TG 48:0 2.70 4.67 0.44 Increase 
3 PC 37:5e 1.24 1.89 0.45 Increase 
4 TG 18:0 18:1 18:2 0.98 1.60 0.08 Increase 
5 TG 4:0 18:1 16:0 0.89 1.42 0.16 Increase 
6 TG 4:0 18:1 14:0 0.93 1.43 0.16 Increase 
7 TG 16:1 18:1 18:1 0.99 1.30 0.11 Increase 
8 TG 10:0 10:0 12:1 1.15 1.62 0.40 Increase 
9 TG 4:0 16:0 18:2 0.90 1.36 0.19 Increase 
10 TG 4:0 16:0 20:4 0.87 1.35 0.14 Increase 
11 TG 18:1 18:3 22:1 0.94 1.14 0.05 Increase 
12 TG 4:0 14:0 16:0 1.14 1.00 0.44 Decrease 
13 PS 18:0 20:4 1.07 1.34 0.21 Increase 
14 TG 16:0 14:0 20:3 1.07 1.35 0.25 Increase 
15 TG 18:0 14:0 18:3 1.11 0.96 0.16 Decrease 
16 PE 40:8e 0.96 1.14 0.01 Increase 
17 TG 19:0 18:1 18:2 1.12 0.97 0.37 Decrease 
18 TG 4:0 16:0 20:5 0.87 1.26 0.15 Increase 
19 PC 20:4e 18:0  0.93 1.10 0.10 Increase 
20 TG 18:3 18:3 18:3 0.96 1.13 0.18 Increase 
  *e - ether lipid 
Three out of these lipids are incompletely identified, TG 48:0, PC 37:5e and PE 40:8e. TG 48:0 
and PC 37:5e are the second and third most important lipids for the separation in the model, but 
as they have not been completely identified there is unfortunately not possible to know what 
lipid this is. Out of the 20 lipids, 17 showed an increase in ratio in the vitamin D group compared 
to placebo, while 3 showed a decrease. Nevertheless, only two of the lipids showed significant 
difference between vitamin D group and placebo group (p≤0.05), PE 40:8e and TG 18:1 18:3 
22:1. Regrettably, PE 40:8e was not completely identified and the distribution over the fatty 
acids are unknown.  
An interesting observation of these results was that 6 of the lipids contained butyrate, a four-
carbon short-chain fatty acid (SCFA), and 5 of these were upregulated in the vitamin D group, 
though not significant. SCFAs, such as butyrate, are organic acids produced in the intestinal 
lumen by bacterial fermentation of partially or nondigestible polysaccharides. Butyrate has 
received attention for its beneficial effects on intestinal homeostasis and cellular energy 
metabolism. Butyrate has also been shown to play an important role in modulating immune and 




inflammatory effects through inhibition of NF-κB, a transcription factor that regulates the 
expression of a variety of genes involved in inflammation and immunity, and upregulation of 
PPAR-γ, a member of the nuclear hormone family whose activation is thought to exert anti-
inflammatory effects (53).  
In genetically predisposed patients with inflammatory bowel disease there is an abnormal 
immune response to gut microbiota. This presents itself with less diverse and imbalanced gut 
microbiota composition, with a lower abundancy of butyrate producing species. It has been 
shown that vitamin D supplementation and the anti-inflammatory effect of VDR are directly 
associated with the gut microbiota (54). Schäffler et al. (55) reported that vitamin D 
supplementation temporarily increased the abundance of beneficial bacteria in remission 
Crohn’s disease patients, but not in healthy controls. Among these is Faecalibacterium, whose 
characteristic is producing butyrate which has been shown to be a way to reduce inflammation. 
This study only had 17 participants, 7 with Crohn’s disease and 10 healthy controls with vitamin 
D deficiency. All the participants in both groups received a total of 300 000 IU of vitamin D 
supplementation over the course of 4 weeks (55). The results of this thesis indicate that the 
participants in the vitamin D group show elevated levels of butyrate in the form of TG in SAT, 
compared to the placebo group. The mechanism for this could perhaps be attributed to the 
increase of beneficial bacteria in the gut microbiota.  
The participants of this thesis are healthy subjects with no chronic diseases. Schäffler et al. 
showed no increase in the abundance of beneficial bacteria in healthy subjects, and in 
participants with Crohn’s disease showed an increase that would decrease again towards the 
end. The study had few participants and a shorter intervention time. Schäffler et al. speculated 
that the temporary increase could either be because vitamin D only had a temporary effect on 
the bacterial communities, there is an optimal vitamin D level window, or that 4 weeks is too 
early to see long-term effects of vitamin D on the composition of the bacterial communities 
(55). In this thesis, there were more participants, 51 participants with 26 in placebo group and 
25 in vitamin D group, with 2 months of intervention. An upregulation of butyrate in the form 
of TGs is observed. There is a possibility that with a larger study with more participants, 
increase in SCFA producing bacteria could also be seen in healthy subjects. It could also be 
speculated that 2 months of supplementation could be enough to see a long-term effect of 




3 of the lipids contained 20:4, this could be the polyunsaturated fatty acid, arachidonic acid. In 
a study on maternal rats, rats receiving vitamin D deficient diet demonstrated higher 
arachidonic acid levels in both plasma and liver compared to controls which received a 1000 
IU/kg diet. Therefore, indicating that maternal vitamin D deficiency may be associated with 
increased inflammation as arachidonic acid is known to produce proinflammatory mediators 
(56). The 3 lipids containing 20:4 all showed an increase in vitamin D group, though 
insignificantly. In this thesis, adipose tissue is investigated and not plasma or liver which could 
demonstrate a different outcome. A possible explanation could be that as an increased amount 
of 20:4 is found bound to TG, less is available to produce proinflammatory mediators and 
therefore reduce the inflammatory response. Nevertheless, as it is not known where the double 
bonds are located in the fatty acid, it could also possibly be the omega 3 isomer of 
eicosatetraenoic acid, which is a precursor of the omega 3 fatty acids eicosapentaenoic acid 
(20:5) and docosahexaenoic acid (22:6) which is known for exhibiting anti-inflammatory 
properties. Out of the 20 lipids in the data set one contains 20:5, also demonstrating an increase, 
though not significant. Though in the same study by Nandi et al. mentioned earlier, no change 
in plasma and liver omega 3 was observed, which could possibly be explained by compromised 
activity of desaturases in the omega 3 fatty acid metabolism pathway due to these desaturases 
being competitive and may be active in omega 6 metabolic pathway (56). If there is no 
competition from the omega 6 metabolic pathway with arachidonic acid, there could be a 
possibility of observing an increase in omega 3 fatty acids. Nonetheless, this is not certain and 






4.5  Other Analyses 
In addition to the MVA, it was performed a pathway analysis, enrichment analysis, and a 
biomarker analysis on the 10 most important lipids for the OPLS model. The biomarker analysis 
was not able to identify any potential biomarkers among the 10 lipids. For the enrichment and 
pathway analysis, over half of the compounds IDs could not be matched to MetaboAnalyst’s 
database. MetaboAnalyst obtained their lipids from the databases LIPID MAPS and RefMet 
but was not able to match all uploaded compound names to their internal compound database. 
The low identification rate may have caused the enrichment analysis to not show any 
noteworthy results.  
Nevertheless, the pathway analysis was able to identify one pathway with more than one hit, 
the glycerophospholipid metabolism pathway, which was somehow different between placebo 
and vitamin D, despite the low identification rate. However, considering pathway impact and 
p-value in order to give an impression of the relevance of the findings, the influence of vitamin 
D on the glycerophospholipid metabolism pathway was not significant (p=0.901, impact 
factor=0,26). Out of the 36 compounds in the glycerophospholipid metabolism pathway, there 
were 4 that matched the dataset. These 4 were PE (C00350), PC (C00157), LPC (C04230), and 
PS (C02737), were LPC has the biggest impact. Within this pathway there is also LPE 
(C04438/C05973), which is also in the dataset but MetaboAnalyst was not able to identify and 
match with KEGG’s pathway database.   




4 of the 20 most influential lipids for the separation between the groups were lipids that are part 
of the glycerophospholipid metabolism pathway, PC 37:5e, PS 18:0 20:4, PE 40:8e and PC 
20:4e 18:0, all of these having an increase after intervention with vitamin D. Though it’s not 
significant, the pathway analysis showed a change in four metabolites of the 
glycerophospholipid metabolism, PE, PC, LPC and PS. In a cancer prevention study where 
baseline serum 25(OH)D and serum metabolites were measured in 392 men from 8 nested 
cancer case-control studies it was found that PE 18:0 20:4 and PE 18:0 18:2 were inversely 
related to serum 25(OH)D. Both glycerophospholipids were also inversely associated with 
aggressive prostate cancer risk (57). Though the role of vitamin D in cancer risk remains 
controversial, a case-cohort study showed no association between circulating 25(OH)D and 
prostate cancer (58). PE 18:0 20:4 was found in the dataset of this thesis. Even though it was 
not shown any significant increase or decrease in the vitamin D group in comparison to the 
placebo group, the lack of significance is most likely caused by large individual differences 
within the groups. In an untargeted clinical metabolomics study in humans, a significant 
reduction of PC after 4 weeks with 15 µg vitamin D daily was detected in the vitamin D 
responsive biomarker cluster characterized by low vitamin D status at baseline (<50 nmol/L) 
and higher plasma concentrations of resistin and adiponectin (59).  
Vitamin D’s connection to other components of the glycerophospholipid metabolism is 
established. A study reported that 1α,25(OH)2D caused a 61% increase in glycerol-3-phosphate 
dehydrogenase (GPDH) activity in human adipocytes, while 1β,25(OH)2D inhibited this effect 
(60). GPDH is an important enzyme of intermediary metabolism and a component of 
glycerophosphate shuttle where it connects glycolysis, oxidative phosphorylation, and fatty 







A sample preparation method to simultaneously extract lipid and metabolites from adipose 
tissue for analysis with UHPLC-MS was developed and tested for both lipids and metabolites. 
Lipid fractions of 102 samples were analyzes by UPLC-MS and data processed, while the 
metabolite fractions are stored at -80ºC awaiting instrument method development and 
validation prior to analysis.  
The result of the multivariate data analysis did not show any separation between vitamin D and 
placebo group in PCA, but showed separation when applying the supervised discriminant 
analysis, OPLS. The OPLS demonstrated that the lipidome in adipose tissue correlates to 
25(OH)D in serum to a greater degree than vitamin D in the adipose tissue. This could indicate 
that the composition of lipids in the adipose tissue is due to vitamin D’s activity not in the 
adipose tissue, but other parts of the body such as the liver.  
Out of the 20 most important lipids that caused the separation between the groups only 2 
showed a significant difference between vitamin D and placebo group. 6 out of the 20 contained 
the short-chain fatty acid butyrate, produced in the intestinal lumen, which could further 
indicate that vitamin D executes its activity outside of the adipose tissue. 4 of the 20 lipids 
contained either 20:4 or 20:5 fatty acids, which could indicate an effect of vitamin D on the 
eicosanoid metabolism.  
The pathway analysis was able to identify the glycerophospholipid metabolism pathway in 
which there was found a difference between vitamin D and placebo group, although it was 
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Appendix 1: Samples 
# Study ID Visit Treatment Serum 25(OH)2D 
(nmol/L) 
 
Fat vitamin D 
(ng/g) 
1 Global 1 1026 Baseline Placebo 41 18 
2 Global 1  Endpoint Placebo 23.6 15 
3 Global 1 1035 Baseline Vitamin D 39 4.2 
4 Global 1  Endpoint Vitamin D 114.6 47 
5 Global 1 1041 Baseline Vitamin D 40 24 
6 Global 1  Endpoint Vitamin D 101.9 53 
7 Global 1 1052 Baseline Vitamin D 42 16 
8 Global 1  Endpoint Vitamin D 86.4 83 
9 Global 1 1055 Baseline Vitamin D 39 22 
10 Global 1  Endpoint Vitamin D 139.2 50 
11 Global 1 1063 Baseline Placebo 24 3.3 
12 Global 1  Endpoint Placebo 11.3 2.5 
13 Global 1 1072 Baseline Vitamin D 45 69 
14 Global 1  Endpoint Vitamin D 77.5 95 
15 Global 1 1081 Baseline Placebo 33 5.2 
16 Global 1  Endpoint Placebo 18 4 
17 Global 1 1091 Baseline Vitamin D 26 25 
18 Global 1  Endpoint Vitamin D 86.4 56 
19 Global 1 1096 Baseline Vitamin D 36 9.4 
20 Global 1  Endpoint Vitamin D 149.1 49 
21 Global 1 1098 Baseline Placebo 38 22 
22 Global 1  Endpoint Placebo 20.4 18 
23 Global 1 1177 Baseline Vitamin D 43 36 
24 Global 1  Endpoint Vitamin D 91.7 104 
25 Global 1 1186 Baseline Placebo 38 11.6 
26 Global 1  Endpoint Placebo 26.1 10.9 
27 Global 1 1187 Baseline Placebo 45 20 
28 Global 1  Endpoint Placebo 21.3 19 
29 Global 1 1188 Baseline Placebo 42 8.8 




31 Global 1 1189 Baseline Placebo 36 5.6 
32 Global 1  Endpoint Placebo 21.3 5.6 
33 Global 1 1200 Baseline Placebo 42 35 
34 Global 1  Endpoint Placebo 22 34 
35 Global 1 1214 Baseline Vitamin D 35 36 
36 Global 1  Endpoint Vitamin D 84 79 
37 Global 1 1228 Baseline Placebo 40 13.9 
38 Global 1  Endpoint Placebo 28 17 
39 Global 2 5715 Baseline Placebo 38.8 104 
40 Global 2  Endpoint Placebo 38.2 108 
41 Global 2 5716 Baseline Placebo 38.4 18 
42 Global 2  Endpoint Placebo 30.6 19 
43 Global 2 5717 Baseline Placebo 46.8 23 
44 Global 2  Endpoint Placebo 39.4 23 
45 Global 2 5718 Baseline Vitamin D 29.9 8 
46 Global 2  Endpoint Vitamin D 96.1 67 
47 Global 2 5719 Baseline Vitamin D 32.9 - 
48 Global 2  Endpoint Vitamin D 89.5 37 
49 Global 2 5720 Baseline Placebo 26.5 8.4 
50 Global 2  Endpoint Placebo 23.8 8.2 
51 Global 2 5721 Baseline Vitamin D 45.8 - 
52 Global 2  Endpoint Vitamin D 86.5 106 
53 Global 2 5722 Baseline Vitamin D 37.2 26 
54 Global 2  Endpoint Vitamin D 83.4 66 
55 Global 2 5723 Baseline Placebo 27.4 4.5 
56 Global 2  Endpoint Placebo 27.8 6.1 
57 Global 2 5724 Baseline Vitamin D 28.3 13 
58 Global 2  Endpoint Vitamin D 86.5 35 
59 Global 2 5725 Baseline Placebo 24.1 18 
60 Global 2  Endpoint Placebo 23.2 19 
61 Global 2 5726 Baseline  Vitamin D 24.7 38 
62 Global 2  Endpoint Vitamin D 92.8 56 
63 Global 2 5727 Baseline Placebo 33.5 15 
64 Global 2  Endpoint Placebo 24.5 10.9 




66 Global 2  Endpoint Vitamin D 73.7 105 
67 Global 2 5729 Baseline Vitamin D 28.1 33 
68 Global 2  Endpoint Vitamin D 99.8 113 
69 Global 2 5730 Baseline Placebo 26.1 10.1 
70 Global 2  Endpoint Placebo 27.1 7 
71 Global 2 5731 Baseline Placebo 30.8 12 
72 Global 2  Endpoint Placebo 35.5 11.4 
73 Global 2 5732 Baseline Vitamin D 35.5 26 
74 Global 2  Endpoint Vitamin D 103.6 86 
75 Global 2 5733 Baseline Placebo 39.7 11 
76 Global 2  Endpoint Placebo 25.7 8.7 
77 Global 2 5734 Baseline Placebo 27.4 19 
78 Global 2  Endpoint Placebo 29.8 19 
79 Global 2 5735 Baseline Vitamin D 30.2 9.1 
80 Global 2  Endpoint Vitamin D 112.6 75 
81 Global 2 5736 Baseline Vitamin D 38.1 17 
82 Global 2  Endpoint Vitamin D 120.5 54 
83 Global 2 5737 Baseline Placebo 37.7 16 
84 Global 2  Endpoint Placebo 29.6 19 
85 Global 2 5738 Baseline Placebo 35.9 24 
86 Global 2  Endpoint Placebo 35.5 18 
87 Global 2 5739 Baseline Vitamin D 27 15 
88 Global 2  Endpoint Vitamin D 92.8 43 
89 Global 2 5740 Baseline Vitamin D 33.1 6.6 
90 Global 2  Endpoint Vitamin D 105.8 44 
91 Global 2 5741 Baseline Placebo 40.7 54 
92 Global 2  Endpoint Placebo 37.1 60 
93 Global 2 5742 Baseline Placebo 37.2 27 
94 Global 2  Endpoint Placebo 29.3 18 
95 Global 2 5743 Baseline Vitamin D 39.9 28 
96 Global 2  Endpoint Vitamin D 118.7 138 
97 Global 2 5744 Baseline Placebo 40.2 33 
98 Global 2  Endpoint Placebo 35.8 48 
99 Global 2 5747 Baseline Vitamin D 26.7 12.1 




101 Global 2 5748 Baseline Vitamin D 35.2 23 
102 Global 2  Endpoint Vitamin D 93.7 89 






Appendix 2: Instrument Settings 
Table 1 Full list of Orbitrap IdX™ Tribrid™ settings for the analysis of the lipidome 
Ion source  
Ion source type  H-ESI 
Spray voltage Static 
Positive/Negative ion (V) 3500/2500  
Sheath gas (arb) 60 
Aux gas (arb) 15 
Sweep gas (arb) 2 
Ion transfer tube temperature (ºC) 350 
Vaporizer temperature (ºC) 350 
MS Global settings  
Method Duration (min) 30 
Infusion mode Liquid chromatography  
Expected LC peak width (s)  3 
Internal mass calibration  Easy-IC 
Data dependent mode Cycle time  
Cycle time (s) 1.5  
MS OT  
Orbitrap resolution  120 000 
Use quadrupole isolation True  
Scan range (m/z) 250-1500  
RF lens (%) 40 
AGC target 400 000  
Maximum injection time (ms) 50 
Polarity  Positive 
Source fragmentation Disabled 
Use EASY-IC True 
Intensity filter  
Minimum intensity  25 000 
Maximum intensity 1E+20 
Dynamic exclusion  
Exclude after n times 1 
Exclusion duration (s) 2 
Exclude isotopes True 
ddMS2 OT HCD  
Isolation mode  Quadrupole 
Isolation window (m/z) 1.5 
Activation type HCD 




Collision energies (%) 25, 30, 35 
Orbitrap resolution 15 000 
Scan range mode Define first mass 
First mass (m/z) 140 
Maximum injection time (ms) 50 
AGC target 50 000 
Microscans 1 
Use EASY-IC True 
ddMS2 OT CID   
Scan priority  1 
Isolation mode  Quadrupole 
Isolation window (m/z) 2 
Activation type CID 
Collision energy mode Fixed 
Collision energy (%) 32 
CID activation time (ms) 10 
Orbitrap resolution 15 000 
Scan range mode Auto 
Maximum injection time (ms) 50 
AGC target 50 000 
Microscans 1 
Use EASY-IC False  
Number of dependent scans 1 
ddMS3 OT  
Scan priority 1 
Isolation window 1.5 
MS2 isolation window 2.2 
Activation type CID 
Collision energy mode Fixed 
Collision energy (%) 35 
Activation time (ms) 10 
Activation Q 0.25 
Orbitrap resolution 15 000 
Scan range mode Auto 
Maximum injection time (ms) 65 
AGC target 50 000 
Microscans 1 
Use EASY-IC False 









Ion source type  H-ESI H-ESI 
Spray voltage Static Static 
Positive/Negative ion (V) 3500/2500  3500/2500  
Sheath gas (arb) 50 50 
Aux gas (arb) 10 10 
Sweep gas (arb) 0 0 
Ion transfer tube temperature 
(ºC) 
325 325 
Vaporizer temperature (ºC) 350 350 
MS Global settings   
Method Duration (min) 16 15 
Infusion mode Liquid chromatography  Liquid chromatography  
Expected LC peak width (s)  3 3 
Internal mass calibration  Easy-IC Easy-IC 
Data dependent mode Cycle time  Cycle time  
Cycle time (s) 0.6 0.6 
MS OT   
Orbitrap resolution  60 000 60 000 
Use quadrupole isolation True True 
Scan range (m/z) 70-800 70-800 
RF lens (%) 35 35 
AGC target 100 000 100 000 
Maximum injection time (ms) 50 50 
Polarity  Positive  Negative 
Source fragmentation Disabled  Disabled  
Use EASY-IC True True 
Intensity filter   
Minimum intensity  20 000 20 000 
Maximum intensity 1E+20 1E+20 
Dynamic exclusion   
Exclude after n times 1 1 
Exclusion duration (s) 2.5 2.5 
Exclude isotopes True True 
ddMS2 OT HCD   
Isolation mode  Quadrupole Quadrupole 
Isolation window (m/z) 1.5 1.5 
Activation type HCD HCD 
Collision energy mode Stepped Stepped 




Orbitrap resolution 30 000 30 000 
Scan range mode Auto Auto 
Maximum injection time (ms) 54 54 
AGC target 50 000  50 000 
Microscans 1 1 
Use EASY-IC False False 
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